


SCQM Foundation Aargauerstrasse 250 8048 Zürich +41 43 268 55 77 scqm@hin.ch www.scqm.ch

### EULAR congress 2024 - five accepted abstracts based on SCQM data

#### OP0034

## DIFFERENTIAL JOINT-LEVEL RESPONSES TO TNF INHIBITORS IN PSORIATIC ARTHRITIS: A COLLABORATIVE EUROPEAN OBSERVATIONAL COHORT STUDY

Session	Clinical Abstract Sessions: Treating clinical aspects of SpA and PsA
Date	Wednesday, 12 June 2024
Time	16:50
Room	A2
Presentation type	Oral
Presenting author	Adrian Ciurea (USZ, Switzerland)



Proportion of the 1729 PsA patients with joint swelling at specified locations at initiation of TNFi.




#### OP0092

INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK-INHIBITORS COMPARED TO bdmards: Findings from an international collaboration of REGISTERS (THE "JAK-POT" STUDY)

Session	Clinical Abstract Sessions: Clinical trials and other treatment aspects in Rheumatoid arthritis
Date	Wednesday, 12 June 2024
Time	17:30
Room	C9
Presentation type	Oral
Presenting author	Romain Aymon (HUG, Switzerland)

Figure 1: Adjusted incidence rate ratios (IRR) with 95% confidence intervals



DMARD: Disease-modifying antirheumatic drug, b/tsDMARD: biologic and targeted synthetic DMARD, CsDMARD: conventional synthetic DMARD, DAS 28: Disease Activity Score 28, HAQ: Health Assessment Questionnaire, GC: glucocorticoids TNFi: tumour necrosis factor inhibitors, OMA: bDMARD with other mode of action, JAKi: janus kinase inhibitors



#### POS0204

# EFFECTIVENESS OF TNF INHIBITION IN VERY EARLY AXIAL SPONDYLOARTHRITIS (LESS THAN ONE YEAR OF AXIAL SYMPTOM DURATION): RESULTS FROM A LARGE NATIONAL OBSERVATIONAL COHORT

Session	Clinical Poster Tours: Treatment of Spondyloarthritis
Date	Thursday, 13 June 2024
Time	14:57
Room	Poster Tour 3
Presentation type	Poster tour
Presenting author	Adrian Ciurea (USZ, Switzerland)

Comparison of TNFi retention in patients with very early and early axSpA versus patients with established axSpA.

Variable	HR	95% CI	Р
Very early vs. established disease	1.05	0.67; 1.64	0.84
Early vs. established disease	0.84	0.62; 1.15	0.28
Age	0.99	0.98; 1.00	0.03
Female sex	1.53	1.23; 1.90	<0.001
Human leucocyte antigen-B27 negativity	1.27	1.02; 1.58	0.03
Education secondary (Ref. mandatory)	0.89	0.67; 1.17	0.39
Education tertiary (Ref. mandatory)	1.02	0.75; 1.38	0.92
Body mass index	1.03	1.00; 1.05	0.03
Current smoking	1.11	0.90; 1.38	0.32
Elevated C-reactive protein	0.57	0.46; 0.71	<0.001
Sacroiliitis on MRI	0.83	0.68; 1.01	0.06



# DOES BIOLOGIC DMARD RETENTION IN AXIAL PSORIATIC ARTHRITIS DEPEND ON THE MODE OF ACTION? COMPARISON OF TNF, IL-17, AND IL-23 INHIBITORS IN A LARGE OBSERVATION COHORT

Session	Clinical Poster Tours: Clinical aspects of psoriatic arthritis
Date	Friday, 14 June 2024
Time	09:54
Room	Poster Tour 2
Presentation type	Poster tour
Presenting author	Adrian Ciurea (USZ, Switzerland)

Mixed-effects Cox proportional hazards models for analysis of drug discontinuation of a bDMARD in PsA patients with axial involvement. (Analysis performed in 364 treatment courses in 275 patients with 244 discontinuation events).


Variable	HR	95% CI	Р
IL-17 inhibitor vs. TNF inhibitor	0.98	0.68; 1.41	0.90
IL23 inhibitor vs. TNF inhibitor	1.01	0.62; 1.63	0.98
Male sex (Ref: female sex)	0.83	0.61; 1.13	0.24
Age	1.00	0.99; 1.01	0.90
Presence of enthesitis	1.26	0.93; 1.73	0.16
Presence of peripheral arthritis	1.36	0.94; 1.97	0.10
Current smoking	0.82	0.56; 1.19	0.30
Obesity (Ref: Body mass index <30)	1.03	0.74; 1.42	0.87
Moderate-severe psoriasis (Ref: mild or no psoriasis)	0.74	0.52; 1.05	0.09
Start treatmen course 2019-2023 (Ref: 2015-2018)	1.31	0.96; 1.79	0.09
1 prior bDMARD failure (Ref: none)	1.07	0.74; 1.54	0.72
2 prior bDMARD failures (Ref: none)	1.23	0.81; 1.85	0.33
≥3 prior bDMARD failures (Ref: none)	0.95	0.61; 1.47	0.80

AB1449



## EXPLORING VACCINATION BEHAVIOUR IN PATIENTS WITH RHEUMATIC DISEASES: FINDINGS FROM A REGISTRY-BASED STUDY (SWISS CLINICAL QUALITY MANAGEMENT)

Session	Across diseases (publication only)
Presenting author	Samia Mehouachi (HUG, Switzerland)



#### OR= Odds Ratio

Being to the right of the vertical line (OR=1) suggests an increased risk of not being vaccinated, while being on the left indicated a decreased risk of the same